Clarametyx touts biofilm study

By The Science Advisory Board staff writers

November 5, 2021 -- Clarametyx Biosciences touted the results of a study published November 3 in Cell that provides insight about components in bacterial biofilms that drive resistance to current medicines.

The research aimed to understand the development and maturation of biofilms to better understand their resistance to the innate immune system. Researchers found that Z-form extracellular DNA (eDNA) is a structural component of the bacterial biofilm matrix (Cell, November 3, 2021).

The company said these findings suggest that the development of therapeutic agents designed to drive biofilm eDNA back into its native B form could prevent or resolve biofilm-mediated diseases.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.